Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel therapeutic strategies for metabolic disorders described in recent patents

Sep. 8, 2006

Glumetza now available in U.S.

Sep. 7, 2006

Recent patents describe new compounds for diabetes and related disorders

Sep. 7, 2006

Enrollment completed in several phase III studies of ferumoxytol

Sep. 7, 2006

RIO trials show efficacy of rimonabant in diabetic and nondiabetic overweight/obese patients

Sep. 7, 2006

eligen technology delivers active recombinant human growth hormone in study

Sep. 7, 2006

Repros updates progress of clinical trials

Sep. 7, 2006

MAXY-G34 for chemotherapy-induced neutropenia studied in phase I

Sep. 7, 2006

alpha-MSH backbone cyclic peptide as a new antiobesity candidate

Sep. 5, 2006

International Trade Commission rules in Roche's favor for Mircera

Sep. 4, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...